Kraig Biocraft Laboratories Successfully Completes Third Commercial Spider Silk Production Cycle
Kraig Biocraft Laboratories (OTCQB: KBLB) has successfully completed its third commercial spider silk production cycle, focusing on BAM-1 recombinant spider silk hybrids. This marks the second successful commercial production of their most advanced spider silk hybrids. The company chose to operate during the rainy season to challenge test the robustness of BAM-1 hybrids and optimize their silkworm colony.
Dr. Nirmal Kumar, a sericulture expert, is analyzing data to guide future production. Over the next two weeks, Kraig Labs will harvest cocoons and send them to local reeling facilities to refine operations and produce additional spider silk for market use. COO Jon Rice emphasized the hybrids' resilience and their role as a catalyst for scalable, commercially sustainable spider silk production.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha completato con successo il suo terzo ciclo commerciale di produzione di seta di ragno, concentrandosi su I ibridi ricombinanti di seta di ragno BAM-1. Questo segna la seconda produzione commerciale di successo dei loro ibridi di seta di ragno più avanzati. L'azienda ha scelto di operare durante la stagione delle piogge per testare la robustezza degli ibridi BAM-1 e ottimizzare la loro colonia di bachi da seta.
Il Dott. Nirmal Kumar, esperto di sericoltura, sta analizzando i dati per guidare la produzione futura. Nei prossimi due settimane, Kraig Labs raccoglierà i bozzoli e li invierà a impianti di filatura locali per affinare le operazioni e produrre ulteriore seta di ragno per l'uso commerciale. Il COO Jon Rice ha sottolineato la resilienza degli ibridi e il loro ruolo come catalizzatori per una produzione di seta di ragno scalabile e sostenibile dal punto di vista commerciale.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha completado con éxito su tercer ciclo comercial de producción de seda de araña, centrándose en los híbridos de seda de araña recombinante BAM-1. Esto marca la segunda producción comercial exitosa de sus híbridos de seda de araña más avanzados. La compañía eligió operar durante la temporada de lluvias para desafiar la robustez de los híbridos BAM-1 y optimizar su colonia de gusanos de seda.
El Dr. Nirmal Kumar, experto en sericultura, está analizando datos para guiar la producción futura. Durante las próximas dos semanas, Kraig Labs cosechará capullos y los enviará a instalaciones locales de reelado para refinar operaciones y producir seda de araña adicional para uso en el mercado. El COO Jon Rice enfatizó la resiliencia de los híbridos y su papel como catalizadores para una producción de seda de araña escalable y comercialmente sostenible.
Kraig Biocraft Laboratories (OTCQB: KBLB)는 BAM-1 재조합 거미 실크 하이브리드에 초점을 맞춘 세 번째 상업적 거미 실크 생산 사이클을 성공적으로 완료했습니다. 이는 그들의 가장 진보된 거미 실크 하이브리드의 두 번째 성공적인 상업적 생산을 의미합니다. 회사는 BAM-1 하이브리드의 견고함을 시험하고 누에 콜로니를 최적화하기 위해 우기 동안 운영하기로 결정했습니다.
세리컬처 전문가인 Nirmal Kumar 박사는 향후 생산을 안내하기 위해 데이터를 분석하고 있습니다. 향후 2주 동안 Kraig Labs는 고치를 수확하고 이를 지역 방적 시설로 보내 작업을 개선하고 시장용 추가 거미 실크를 생산할 것입니다. COO인 Jon Rice는 하이브리드의 회복력과 상업적으로 지속 가능한 거미 실크 생산의 촉매 역할에 대해 강조했습니다.
Kraig Biocraft Laboratories (OTCQB: KBLB) a réussi à compléter son troisième cycle de production commerciale de soie d'araignée, en se concentrant sur les hybrides de soie d'araignée recombinante BAM-1. Cela marque la deuxième production commerciale réussie de leurs hybrides de soie d'araignée les plus avancés. L'entreprise a choisi d'opérer pendant la saison des pluies afin de tester la robustesse des hybrides BAM-1 et d'optimiser leur colonie de vers à soie.
Le Dr. Nirmal Kumar, expert en sériciculture, analyse des données pour guider la production future. Au cours des deux prochaines semaines, Kraig Labs récoltera des cocons et les enverra à des installations locales d'enroulage afin de perfectionner les opérations et de produire de la soie d'araignée supplémentaire pour le marché. Le COO Jon Rice a souligné la résilience des hybrides et leur rôle en tant que catalyseurs pour une production de soie d'araignée évolutive et commercialement durable.
Kraig Biocraft Laboratories (OTCQB: KBLB) hat erfolgreich seinen dritten kommerziellen Produktionszyklus von Spinnenseide abgeschlossen, wobei der Fokus auf BAM-1 rekombinanten Spinnenseide-Hybriden liegt. Dies markiert die zweite erfolgreiche kommerzielle Produktion ihrer fortschrittlichsten Spinnenseide-Hybride. Das Unternehmen entschied sich, während der Regenzeit zu arbeiten, um die Robustheit der BAM-1-Hybride zu testen und ihre Seidenraupen-Kolonie zu optimieren.
Dr. Nirmal Kumar, ein Experte für Seidenproduktion, analysiert Daten, um die zukünftige Produktion zu lenken. In den nächsten zwei Wochen wird Kraig Labs Kokons ernten und sie an lokale Abspinnanlagen senden, um die Abläufe zu verfeinern und zusätzliche Spinnenseide für den Markt zu produzieren. COO Jon Rice betonte die Widerstandsfähigkeit der Hybriden und deren Rolle als Katalysator für eine skalierbare, kommerziell nachhaltige Spinnenseide-Produktion.
- Successful completion of third commercial spider silk production cycle
- Second successful commercial production of advanced BAM-1 spider silk hybrids
- Demonstrated resilience of BAM-1 hybrids by operating during challenging rainy season
- Optimization of silkworm colony for future expansion
- Involvement of sericulture expert Dr. Nirmal Kumar for production analysis and optimization
- None.
ANN ARBOR, Mich., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that it has completed the third commercial spider silk production cycle. This cycle primarily focused on producing the Company's BAM-1 recombinant spider silk hybrids, which marks the second successful commercial production cycle of the Company's most advanced spider silk hybrids.
This production occurred during the region's rainy season, a time of high humidity and heavy rains, which prevents most silk producers from operating. Kraig Labs actively chose to continue production during the rainy season to further challenge test the robustness and resilience of its BAM-1 hybrids.
Operating during the rainy season helped to further optimize the Company’s silkworm colony and identify the best performers and future colony expansion. Renowned sericulture expert Dr. Nirmal Kumar is with the production team to analyze all of the data collected during this rearing cycle and guide the team to optimize the BAM-1 parental lines for continued success and growth of spider silk production.
Over the next two weeks, Kraig Labs will harvest the hybrid spider silk cocoons from this production cycle and send them to local reeling facilities. This batch of cocoons will be used to further refine reeling operations, improve efficiency, and produce additional finished spider silk for use and sale in end markets.
"There is no stiffer challenge for the robustness than operating during the rainy season. Our BAM-1 hybrids demonstrated that they are ready for the worst mother nature can throw at them," said Company COO, Jon Rice. "Our team continues to hit new production and processing milestones with the BAM-1 hybrids as the catalyst for rapid and continuous growth in our scalable and commercially sustainable spider silk production."
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
FAQ
What is the latest achievement of Kraig Biocraft Laboratories (KBLB) in spider silk production?
Why did Kraig Biocraft Laboratories (KBLB) choose to produce spider silk during the rainy season?
What are Kraig Biocraft Laboratories' (KBLB) plans for the harvested spider silk cocoons?
Who is involved in analyzing the production data for Kraig Biocraft Laboratories (KBLB)?
